Document is current
Any future updates will be listed below
-
Authors
Zhang, Tao https://orcid.org/0009-0004-1704-1455
Xu, Daichao https://orcid.org/0000-0002-3286-4968
Liu, Jianping https://orcid.org/0000-0001-7090-2112
Wang, Min
Duan, Li-Juan
Liu, Min
Meng, Huyan https://orcid.org/0000-0003-1511-6156
Zhuang, Yuan
Wang, Huibing
Wang, Yingnan
Lv, Mingming https://orcid.org/0000-0003-4401-7464
Zhang, Zhengyi https://orcid.org/0000-0002-9885-0817
Hu, Jia
Shi, Linyu
Guo, Rui
Xie, Xingxing
Liu, Hui
Erickson, Emily
Wang, Yaru https://orcid.org/0000-0001-8300-0847
Yu, Wenyu
Dang, Fabin https://orcid.org/0000-0002-1954-8231
Guan, Dongxian
Jiang, Cong
Dai, Xiaoming https://orcid.org/0000-0001-9671-8137
Inuzuka, Hiroyuki
Yan, Peiqiang
Wang, Jingchao
Babuta, Mrigya https://orcid.org/0000-0001-8420-4796
Lian, Gewei
Tu, Zhenbo https://orcid.org/0000-0002-3720-7844
Miao, Ji https://orcid.org/0000-0003-0869-4492
Szabo, Gyongyi
Fong, Guo-Hua
Karnoub, Antoine E.
Lee, Yu-Ru https://orcid.org/0000-0001-6592-6806
Pan, Lifeng https://orcid.org/0000-0002-9229-6288
Kaelin, William G. Jr. https://orcid.org/0000-0002-0574-4856
Yuan, Junying https://orcid.org/0000-0003-2405-6036
Wei, Wenyi https://orcid.org/0000-0003-0512-3811
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35CA253027)
- License Information
-
More Information
Article History
Received: 30 December 2021
Accepted: 21 May 2023
First Online: 3 July 2023
Competing interests
: W.W. is a co-founder and consultant for Rekindle Therapeutics. G.S. is paid consultant for Cyta Therapeutics, DURECT, Evive, Merck, Pfizer, Surrozen, Terra Firma, Pandion Therapeutics, Labcorp, Glympse Bio, Satellite Bio and Zomagen. The remaining authors declare no competing interests.
